phoma with villous lymphocytes (SLVL) 4 and in some cases type. 14, 17, 18 We have shown in two cases that biallelic loss of
p16
CDKN2 is a negative regulator of the cell cycle which type. 14, 17, 18 We have shown in two cases that biallelic loss of Keywords: cell cycle; cyclin D1; p16; p15; mantle cell lymphoma p16 CDKN2 accompanied transformation from low-to highgrade disease.
14 Similarly, loss of p16 CDKN2 has also been reported in transformation of 50% of CML cases to lymphoid Introduction blast crisis. 16 In this paper we report the cytogenetic, molecular and bioAbnormalities involving the negative and the positive regulogical characterization of a new B-NHL cell line with mullators of the cell cycle have been reported in a wide variety tiple translocations and concurrent abnormalities of the cyclin of tumors. In lymphoid malignancies, deregulation of the D1, p16 CDKN2 and p15 CDKN2B genes. cyclin D1 gene is found specifically in more than 80% of mantle cell NHL (Mc-NHL) cases, 1-3 in 10% of splenic lym-widespread intra-abdominal lymphadenopathy (maximally with zinc-inducible overexpression of cyclin D1, established upon stable transfection of a cyclin D1 cDNA under control 2 cm diameter) and splenomegaly. Full blood count was hemoglobin 10 g/l, white cell count (WCC) 3.0 × 10 9 /l, plateof the methalothionein promoter. 8 The T47D/D1-D3 cells lack  any p16 CDKN2 protein as a result of loss of one allele and prolets 14 × 10 9 /l. Bone marrow aspirate and trephine showed a hypercellular marrow with complete replacement of normal moter silencing of the other allele (our unpublished data); they were cultured in serum-free medium supplemented with insucells by large lymphoid cells with open chromatin, multiple nucleoli and high nuclear/cytoplasmic ratio. Immunophenolin and transferrin, 8 and the optimal concentration of zinc sulfate to induce cyclin D1 expression is 40 m (Ref. 8; confirmed typing by flow cytometry was consistent with a mature clonal B cell population namely: IgM (76%), CD19 (85%) HLA-DR in our laboratory). MCF-7 is a breast carcinoma cell line 24 which exhibits high levels of cyclin D1 and Cdk4 25 and was (64%), CD5 (63%). All T cell and myeloid markers were negative. A diagnosis of high grade B-NHL (stage IV) was made on used for positive control for Cdk4 expression. the basis of bone marrow findings, and she was treated with high-dose combination chemotherapy including high-dose cyclophosphamide, and methotrexate, VP16, bleomycin, Immunophenotyping and immunocytochemistry vincristine and prednisolone. She initially made a good response, with normalization of counts but by September she Expression of cell surface antigens was determined by flow cytometry using a panel of lineage-specific monoclonal antibodies presented with a WCC of 750 × 10 9 /l, composed of lymphomatous blasts. Repeated immunophenotyping was identical (MoAbs) as described. 26 Expression of p53 was determined by immunocytochemistry as described 27 using the 1801 p53 MoAb apart from loss of CD5 expression. The cell line Granta 519 was established from a peripheral blood sample taken at this antibody (Oncogene Science, Cambridge, MA, USA). time. No further therapy was given and she died shortly thereafter. No post-mortem examination was performed.
DNA and RNA analysis
Probes:
pPL-8 is a 1.4-kb EcoRI cDNA probe from the Case 75
cyclin D1 gene and is a subclone of Lp1-4. 28 The Cdk4 probe is a 500-bp PCR product, pK4-PCR, which contains exonic Case 75 was a patient who presented in December 1993 at the age of 81, with incidental finding of a peripheral blood and intronic sequences of the Cdk4 gene. 29 The p16 CDKN2 probe is a 300-bp fragment containing the coding region of lymphocytosis. Immunophenotyping by flow cytometry produced the following results: IgM (80%) IgD (72%) CD19 exon 1 of p16 CDKN2 (130-bp) plus 200-bp of flanking sequences. The probe was obtained by PCR amplification (97%) CD5 (80%) CD10 (78%). No tissue was available for histological analysis. However, on the basis of morphology, from normal human genomic DNA using described primers. 30 The p15 CDKN2B probe is a 2-kb EcoRI-XhoI full length cDNA bright staining intensity of the surface immunoglobulins and CD5 positivity the patient was diagnosed as Mc-HNL. In fragment from the p15 CDKN2B gene. 31 p18 is a 520-bp cDNA fragment from the open reading frame of the p18 gene. 32 The 1994, shortly before the patient died, the white cell morphology had become more bizarre and blast-like than the glyceraldehyde-3-phosphate dehydrogenase probe (GAPDH) is a rat cDNA. 33 presentation picture, with numerous large nucleated cells in the circulation, and the tumor was regarded morphologically as a high-grade lymphoma. Polymerase chain reaction (PCR) and DNA sequencing: Total RNA from the Granta 519 cell line was reverse transcribed using superscript reverse transcriptase (Gibco-BRL,
Materials and methods
Gaithersburg, MD, USA) and an oligo dT-primer. The entire open reading frame of the cyclin D1 gene was amplified using
Cell culture, cytogenetics, cell lines and FISH forward primer C: 5′TCCGGCGAGGGGCAGAAGA3′ and reverse primer D: 5′TGCGGGGTCATTGCGGCCAG3′ as Granta 519 was established as a spontaneously growing cell line from a peripheral blood sample as described. 19 Cytogendescribed. 34 The 1004-bp PCR product was cloned in the pGEMT vector (Promega, Madison, WI, USA) and sequenced etics were performed as described. 20 Briefly, cells were synchronized with ethidium bromide and harvested 24 and 28 h using single-stranded DNA, with Taquence (Amersham, Little Chalfont, UK). after the initiation of culture and at intervals of 4 weeks thereafter using routine methods. Chromosome preparations were G-banded with Wright's stain, and high-resolution banding analysis was performed assisted by computer-based image-PCR analysis of sequence tag site (STS) markers: The primer sequence and PCR conditions used for amplification analysis system (Smart Capture; Digital Scientific, Cambridge, UK). The ISSN 1991 nomenclature was used to describe the of STSs located within, proximal and distal of the p16 CDKN2 and p15 CDKN2B genes were as described. 30 abnormal chromosome markers. Three B cell tumor cell lines with translocation t(11;14)(q13;q32) or 11q13 abnormalities were used as positive control for cyclin D1 gene expression and were as fol-PCR amplification and sequencing of the p53 gene: Exons 5, 6, 7, 8, 9 of the p53 gene were amplified from genomic lows: NCEB-1, derived from a patient with diffuse centroblastic-centrocytic lymphoma 21 Karpas 620; a myeloma cell DNA. Both strands were sequenced directly for each exon, using an ABI 373A (Foster City, CA, USA) automated line 22 and JVM-2; a B cell prolymphocytic leukemia cell line.
23 JVM-13 a B cell prolymphocytic cell line with no sequencer and the following primers: exon 5 sense strand: 5′ACTTGTGCCCTGACTTTCAACT 3′; exon 5 antisense t(11;14) translocation, 23 was used as negative control for cyclin D1 expression. T47D/D1-D3 is a breast cancer cell line strand: 5′CAATCAGTGAGGAATCAGAGGC 3′; exon 6 sense 
Results

RNA analysis and cyclin D1 gene expression in Granta 519:
RNA analysis and Northern blotting were as Cytogenetic and immunophenotypic analysis described. 4 Briefly, RNA was isolated by the guanidinium isothiocynate/cesium chloride method. 35 RNA was electroph-G banding analysis of the initial peripheral blood sample showed the presence of a major clone and additionally two oresed through denaturing formaldehyde-1.1% agarose gels and transferred to nylon filters. 36 Hybridization with the minor clones with complex chromosome rearrangements. The same abnormalities were found in the derived Granta 519 cell GAPDH probe was used to document the quality and equal loading of RNA in each lane. line indicating that no major cytogenetic abnormalities occurred during the establishment of the cell line. No other chromosome changes were observed after 3 years in intermittent culture.
Immunochemical techniques and kinase assays
The karyotypic analysis showed the following chromosome rearrangements: (1) Major cell clone: 44,XX,−1, Monoclonal antibodies to cyclin D1, 37 cyclin D2, 38 cyclin D3 39 and pRB 40 were described previously. DCS-31 is a mouse der(1)t(1;12)(p22;?), −8,−9, der(9)t(9;?)(p22;?) −11, der(11) t(11;14)(q13;q32), −12, −13, der(13)t(13;?)(p12;?) −14, der(14) MoAb specific for Cdk4 (Bartek et al, manuscript in preparation). Rabbit antisera against Cdk4 and Cdk6 were t(11;14)(q13;q32), −17, der (17) (14) marker chromosome and absence of a normal chromosome protocols were as reported previously. 37 For kinase assays, immunoprecipitated cyclin-Cdk complexes bound to protein G 14 homolog. (3) Minor clone 2: hypotetraploid version of the major cell clone. A representative metaphase cell and partial beads were washed in the extraction and kinase buffers, followed by kinase reaction, 41 using a bacterially produced GSTkaryotypes of the abnormal chromosomes are shown in Figure 1 . RB C-terminus (pRB amino acids 773-928) fusion protein as a substrate. 42 The reaction was stopped by addition of electroThe cell line Granta 519 has the immunophenotype of a mature B cell malignancy as shown in Table 1 . phoresis sample buffer, separated on 10% polyacrylamide gels, and phosphorylated pRB visualized by phosphorimaging.
Granta 519 cell line expresses high levels of cyclin D1 mRNA and is biallelically deleted for the Gene transfer by electroporation p16 CDKN2 and p15 CDKN2B genes Granta 519 cells were pre-synchronized in M phase by culture in medium with 40 ng/ml nocadazole for 20 h. MitosisIn view of the observed t(11;14)(q13;q32) cyclin D1 expression was determined by Northern blotting. Granta 519 enriched cells (2.5 × 10 6 ) were washed, resuspended in PBS, and mixed with 10 g of pX myc p16 expression plasmid 43 in cells expressed high levels of cyclin D1 mRNA with the small 1.7-kb mRNA species being the most abundant. Furthermore, a final volume of 50 l. Pulse was delivered using Bio-rad (Hercules, CA, USA) Gene Pulser apparatus with the following Granta 519 expressed higher levels of cyclin D1 mRNA in comparison with other B cell lines with t(11;14)(q13;q32) or settings: 270V; 125 FD; infinite resistance. The electroporated cells were transferred into fresh medium and grown for 11q13 abnormalities (Figure 2) .
Mutations within the open reading frame of the cyclin D1 72 h, with bromodeoxyuridine (BrdU) at 100 m added for the last 6 h of culture. The cells were harvested by centrifugation, gene were sought by reverse transcription and polymerase chain reaction (RT-PCR) and sequencing. No point mutations resuspended in a drop of fetal calf serum, and spread over glass slides. After drying at room temperature, the cell smears within the coding sequence of the gene were detected.
To determine the involvement of the p16 CDKN2 tumor supwere fixed in cold methanol-acetone (1:1 by volume) for 10 min and double stained with the DCS-50 mouse MoAb 43 to pressor gene in this cell line we used Southern blotting and found that p16 CDKN2 was biallelically deleted (Figure 3a and p16 CDKN2 visualized by the Texas red-conjugated anti-mouse immunoglobulin (Vector Laboratories, Peterborough, UK), b). The extent of the deletions were determined by PCR using nine STS markers located within, proximal and distal of the and FITC-conjugated anti-BrdU antibody as described. 44 Trypsinized T47D/D1-D3 breast cancer cells were electroporated p16 CDKN2 gene. 30 All STS markers were homozygously deleted indicating that the deletion spanned a minimum region of with the p16 CDKN2 expression plasmid using the same parameters as for Granta cells, replated in medium with 5% fetal 70 kb and included the p15 CDKN2B gene. Biallelic deletion of the p15 CDKN2B gene was further confirmed by Southern blotbovine serum to recover overnight, then cultured in serumfree medium with insulin and transferrin 8 for 48 h to reach the ting using a p15 CDKN2B cDNA probe (data not shown). Since mutations of p53 and p16
CDKN2 aberrations can occur basal proliferation rate, and parallel cultures were then treated with either 40 m zinc sulfate or the control buffer lacking in the same tumour, 45, 46 we looked for p53 mutations. No 47 Comparative immunoblotting analysis showed that cyclin D1 is clearly dominant among the D-type cyclins +, weak positive expression; ++, strong expression; +++, very strong since cyclin D2 was undetectable and cyclin D3 was only expression; −, no detectable expression. present at a relatively low level (Table 2) . Immunofluorescence analysis with MoAbs specific for individual D-type cyclins confirmed the immunoblotting data, and revealed a p53 expression was detected by immunocytochemistry. Direct sequencing of exons 5-9 of the p53 gene was also performed.
predominantly nuclear localization of the cyclin D1 and D3 proteins (data not shown). Of the two functional partners These exons harbor most point mutations identified in the p53 gene. The results showed a wild-type p53 in Granta 519.
of D-type cyclins, Cdk4 was significantly more abundant than Cdk6 (Figure 4a and Table 2 ). The p16
CDKN2
Immunoblotting analysis showed that Granta 519 expressed higher levels of Cdk4 in comparison with other B-NHL cell protein was undetectable by either immunoblotting or immunofluorescence. lines with t(11;14)(q13;q32) and germline p16 with antibodies to cyclin D1 or Cdk4 detected an abundant comitant occurrence of cyclin D1 and p16 CDKN2 abnormalities. One experimentally testable prediction of a potential cocomplex of these two proteins (Figure 5a ). The immunoprecipitated complexes of cyclin D1 and Cdk4 were active as pRB operative effect of cyclin D1 and p16 CDKN2 aberration would be that the Granta 519 cells may still be sensitive to reintrokinase, as demonstrated in Figure 5b . Lower but detectable pRB kinase activity was also co-precipitated with antibody duction of a wild-type p16 CDKN2 . Electroporation of pre-synchronized Granta 519 cells with an expression plasmid 43 encospecific for cyclin D3 (Figure 5b) , consistent with the relative abundance of the individual D-type cyclin proteins, the lack ding wild-type human p16 CDKN2 resulted in clearly detectable expression of the p16 CDKN2 protein in a subpopulation of cells, of the p16 CDKN2 and p15 CDKN2B inhibitors, and functional pRB in Granta 519 cells.
as monitored by immunofluorescence analysis (Figure 6a ). More significantly, ectopic expression of the p16
Cyclin D1, which is aberrantly expressed in the Granta 519 cell line, is thus clearly functional (this study) and is required efficiently prevented these cells from entering S phase as determined by concurrent evaluation of bromodeoxyuridine for cell cycle progression in vivo. 47 The question remained whether the concurrent loss of p16 CDKN2 could also provide incorporation (Figure 6b ). The extent of G1 arrest/S phase entry inhibition in Granta 519 cells expressing p1 CDKN2 was a growth advantage to such tumor, as suggested by the con- 
Table 2
Expression and function of the major components of the rence of the two events. To this end, we took advantage of gically high grade B-NHL. As the patient presented with bone marrow failure and had no lymph node biopsy, precise histological classification was not possible. However, the expression of CD5 on the presentation bone marrow sample highly reproducible, and the data from three independent experiments is summarized graphically in Figure 6c .
and the presence of a t(11;14)(q13;q32) make it likely that the case represented a blastic transformation of Mc-NHL. Granta These results were consistent with a possible co-operative effect of the cyclin D1 and p16 CDKN2 aberrations in the Granta 519 exhibited numerous and complex cytogenetic abnormalities involving chromosomes 9p22, 13p11, 17p11, and 18q21. 519 cell line, however, direct evidence for such co-operation required an experimental system mimicking a stepwise occurGranta 519 also exhibited concurrent abnormalites of cyclin CDKN2B , major regulators of the G1 phase of the cell cycle, and expressed higher levels of cyclin D1 mRNA than other B cell lines with t(11;14). High levels of cyclin D1 mRNA due to mutations or rearrangements within the 3′ untranslated region of the cycin D1 gene which alter the AUUUA destabilizing signal leading to a significant increase of the half-life of the mRNA, as have been shown in a breast carcinoma cell line 48 and in some leukemia and lymphoma cell lines 49, 50 have not been excluded. It should be noted that the cyclin D1 overabundance at the protein level is less pronounced, being comparable with that seen in some other human cancer cell lines. 47, 51 Among the B-NHL cell lines which we have examined, Granta 519 is unique in having concurrent cyclin D1 overexpression and biallelic p16 CDKN2 and p15 CDKN2B deletions. These deletions were greater than 70 kb but were not detectable cytogenetically. Whether or not the p16 CDKN2 /p15 CDKN2B genes were lost during the establishment of the cell line rather than in the patient's original tumor cell population, could not be ascertained, although the total lack of these genes at the relatively early passage of Granta cells is consistent with the former scenario. Furthermore, p16
CDKN2 biallelic deletion has been noted in NHL at a low frequency principally in high grade and transformed cases of both B and T cell lineages.
14 We have also observed similar deregulation of cyclin D1 mRNA and biallelic deletion of p16 CDKN2 in a fresh case (case 75) of CDKN2 , and pRB represent alternaautomated DNA sequencing facility. We thank R Hamoudi for his help with the p53 sequence analysis. tive targets within a common path towards malignancy, with any of these abnormalities having analogous effect upon deregulation of the cell cycle.
While such conclusion appears justified based on the mutuReferences ally exclusive pattern of RB gene defects and any other 
